These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 27322073)

  • 1. Could Killing Bacterial Subpopulations Hit Tuberculosis out of the Park?
    Baranowski C; Rubin EJ
    J Med Chem; 2016 Jul; 59(13):6025-6. PubMed ID: 27322073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimising moxifloxacin resistance with tuberculosis.
    Drlica K; Zhao X; Kreiswirth B
    Lancet Infect Dis; 2008 May; 8(5):273-5. PubMed ID: 18471768
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.
    Gold B; Smith R; Nguyen Q; Roberts J; Ling Y; Lopez Quezada L; Somersan S; Warrier T; Little D; Pingle M; Zhang D; Ballinger E; Zimmerman M; Dartois V; Hanson P; Mitscher LA; Porubsky P; Rogers S; Schoenen FJ; Nathan C; Aubé J
    J Med Chem; 2016 Jul; 59(13):6027-44. PubMed ID: 27144688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relevance of persisters in tuberculosis drug discovery.
    Mandal S; Njikan S; Kumar A; Early JV; Parish T
    Microbiology (Reading); 2019 May; 165(5):492-499. PubMed ID: 30775961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013.
    Maitra A; Bhakta S
    Virulence; 2013 Aug; 4(6):499-503. PubMed ID: 23863609
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of drug resistant tuberculosis].
    Perel'man MI; Sokolova GB; Borisov SE; Kunichan AD; Lazareva IaV; Mozhokina GN; Elistratova NA; Tsybanev AA
    Antibiot Khimioter; 2003; 48(8):28-36. PubMed ID: 14722939
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sensitivity of Mycobacterium tuberculosis in our environment].
    Unzaga MJ; Sota M; Melero P; Berdonces P; Ezpeleta C; Cisterna R
    Enferm Infecc Microbiol Clin; 1996; 14(6):399-400. PubMed ID: 8756225
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis.
    Eilertson B; Maruri F; Blackman A; Herrera M; Sterling TR
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1276-7. PubMed ID: 27510259
    [No Abstract]   [Full Text] [Related]  

  • 9. Reactive dirty fragments: implications for tuberculosis drug discovery.
    Gopal P; Dick T
    Curr Opin Microbiol; 2014 Oct; 21():7-12. PubMed ID: 25078318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid?
    Velayati AA; Farnia P; Masjedi MR; Hoffner S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):849-50. PubMed ID: 23676176
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of new anti-tuberculosis drug candidates.
    Shi R; Sugawara I
    Tohoku J Exp Med; 2010 Jun; 221(2):97-106. PubMed ID: 20467231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiology. TB--a new target, a new drug.
    Cole ST; Alzari PM
    Science; 2005 Jan; 307(5707):214-5. PubMed ID: 15653490
    [No Abstract]   [Full Text] [Related]  

  • 13. [Short-term chemotherapy of tuberculosis in Chile. Bacteriological considerations].
    Valenzuela P
    Rev Med Chil; 1983 Jul; 111(7):747-9. PubMed ID: 6440255
    [No Abstract]   [Full Text] [Related]  

  • 14. [Phage amplified biologically assay and its application in rapid detection of Mycobacterium tuberculosis].
    Hu ZY
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Dec; 27(12):850-2. PubMed ID: 15730788
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.
    Sacchettini JC; Rubin EJ; Freundlich JS
    Nat Rev Microbiol; 2008 Jan; 6(1):41-52. PubMed ID: 18079742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shortening the treatment of tuberculosis.
    Mitchison DA
    Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
    [No Abstract]   [Full Text] [Related]  

  • 17. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First- and second-line antituberculosis drug resistance patterns among previous treatment failure patients in Myanmar.
    Nyunt WW; Aung ST; Lwin T; Cook GM; Aung HL
    J Glob Antimicrob Resist; 2017 Jun; 9():34-35. PubMed ID: 28323227
    [No Abstract]   [Full Text] [Related]  

  • 19. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance of Mycobacterium tuberculosis to daptomycin.
    Moon C; Jang JC
    Infect Dis (Lond); 2016 Jul; 48(7):569-70. PubMed ID: 27117762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.